169 related articles for article (PubMed ID: 18680276)
1. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.
Pasquini S; Botta L; Semeraro T; Mugnaini C; Ligresti A; Palazzo E; Maione S; Di Marzo V; Corelli F
J Med Chem; 2008 Aug; 51(16):5075-84. PubMed ID: 18680276
[TBL] [Abstract][Full Text] [Related]
2. Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.
Pasquini S; De Rosa M; Pedani V; Mugnaini C; Guida F; Luongo L; De Chiaro M; Maione S; Dragoni S; Frosini M; Ligresti A; Di Marzo V; Corelli F
J Med Chem; 2011 Aug; 54(15):5444-53. PubMed ID: 21702498
[TBL] [Abstract][Full Text] [Related]
3. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
[TBL] [Abstract][Full Text] [Related]
4. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.
Pasquini S; Ligresti A; Mugnaini C; Semeraro T; Cicione L; De Rosa M; Guida F; Luongo L; De Chiaro M; Cascio MG; Bolognini D; Marini P; Pertwee R; Maione S; Di Marzo V; Corelli F
J Med Chem; 2010 Aug; 53(16):5915-28. PubMed ID: 20718492
[TBL] [Abstract][Full Text] [Related]
5. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
[TBL] [Abstract][Full Text] [Related]
7. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
[TBL] [Abstract][Full Text] [Related]
8. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
9. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
[TBL] [Abstract][Full Text] [Related]
10. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
Trotter BW; Nanda KK; Burgey CS; Potteiger CM; Deng JZ; Green AI; Hartnett JC; Kett NR; Wu Z; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2011 Apr; 21(8):2354-8. PubMed ID: 21420860
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
[TBL] [Abstract][Full Text] [Related]
13. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
[TBL] [Abstract][Full Text] [Related]
14. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.
Pasquini S; Mugnaini C; Ligresti A; Tafi A; Brogi S; Falciani C; Pedani V; Pesco N; Guida F; Luongo L; Varani K; Borea PA; Maione S; Di Marzo V; Corelli F
J Med Chem; 2012 Jun; 55(11):5391-402. PubMed ID: 22548457
[TBL] [Abstract][Full Text] [Related]
16. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
[TBL] [Abstract][Full Text] [Related]
17. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.
Mugnaini C; Brizzi A; Ligresti A; Allarà M; Lamponi S; Vacondio F; Silva C; Mor M; Di Marzo V; Corelli F
J Med Chem; 2016 Feb; 59(3):1052-67. PubMed ID: 26756097
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of novel purines as potent and selective CB2 agonists.
Hollinshead SP; Astles PC; Chambers MG; Johnson MP; Palmer J; Tidwell MW
Bioorg Med Chem Lett; 2012 Aug; 22(15):4962-6. PubMed ID: 22765893
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
20. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
